Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 7Multiple Myeloma 6Lymphoma, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Recurrence 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Glioma 3Astrocytoma 3Sarcoma 2Melanoma 2Lymphoma 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Metastatic Hormone-Sensitive Prostate Cancer 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

fludarabine 2Cyclophosphamide 2siltuximab 1fludarabine phosphate 1Leukapheresis 1Bendamustine Hydrochloride 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cytokine Release Syndrome × Leukapheresis × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡